In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sandoz, Momenta sign $75mm generics deal

Executive Summary

Momenta Pharmaceuticals (engineering complex sugars) has agreed to work with Novartis's Sandoz generics division to exclusively develop four follow-on complex generic versions of already approved recombinant therapeutics.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Equity
    • Reverse Licensing
    • Product or Technology Swap
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register